Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021;14:101174. https://doi.org/10.1016/j.tranon.2021.101174

Article  PubMed  PubMed Central  Google Scholar 

Hossain MS, Karuniawati H, Jairoun AA, Urbi Z, Ooi J, John A, Lim YC, Kibria KMK, Mohiuddin AKM, Ming LC, Goh KW. Hadi,Colorectal Cancer: a review of Carcinogenesis, Global Epidemiology, Current challenges, risk factors, preventive and treatment strategies. Cancers (Basel). 2022;14. https://doi.org/10.3390/cancers14071732

Rawla P, Sunkara T. Barsouk,Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Gastroenterol Review/Przegląd Gastroenterologiczny. 2019;14:89–103.

CAS  PubMed  Google Scholar 

Vodenkova S, Buchler T, Cervena K, Veskrnova V, Vodicka P. Vymetalkova,5-fluorouracil and other fluoropyrimidines in colorectal cancer: past, present and future. Pharmacol Ther. 2020;206:107447.

Article  CAS  PubMed  Google Scholar 

Sethy C. Kundu,5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: implication of DNA repair inhibition. Biomed Pharmacother. 2021;137:111285.

Article  CAS  PubMed  Google Scholar 

Longley DB, Harkin DP. Johnston,5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3:330–8. https://doi.org/10.1038/nrc1074

Article  CAS  PubMed  Google Scholar 

Sanchez-Gundin J, Fernandez-Carballido AM, Martinez-Valdivieso L, Barreda-Hernandez D. Torres-Suarez,New trends in the Therapeutic Approach to Metastatic Colorectal Cancer. Int J Med Sci. 2018;15:659–65. https://doi.org/10.7150/ijms.24453

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kasprzak A, Adamek A. The Neuropeptide System and Colorectal Cancer Liver metastases: mechanisms and management. Int J Mol Sci. 2020;21. https://doi.org/10.3390/ijms21103494

Chen XY, Ru GQ, Ma YY, Xie J, Chen WY, Wang HJ, Wang SB, Li L, Jin KT, He XL. Mou,high expression of substance P and its receptor neurokinin-1 receptor in colorectal cancer is associated with tumor progression and prognosis. Onco Targets Ther. 2016;9:3595–602. https://doi.org/10.2147/OTT.S102356

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lorestani S, Ghahremanloo A, Jangjoo A, Abedi M. Hashemy,evaluation of serum level of substance P and tissue distribution of NK-1 receptor in colorectal cancer. Mol Biol Rep. 2020;47:3469–74. https://doi.org/10.1007/s11033-020-05432-4

Article  CAS  PubMed  Google Scholar 

Munoz M. Covenas,involvement of substance P and the NK-1 receptor in human pathology. Amino Acids. 2014;46:1727–50. https://doi.org/10.1007/s00726-014-1736-9

Article  CAS  PubMed  Google Scholar 

Ebrahimi S, Javid H, Alaei A. Hashemy,New insight into the role of substance P/neurokinin-1 receptor system in breast cancer progression and its crosstalk with microRNAs. Clin Genet. 2020;98:322–30. https://doi.org/10.1111/cge.13750

Article  CAS  PubMed  Google Scholar 

Ghahremani F, Sabbaghzadeh R, Ebrahimi S, Javid H, Ghahremani J. Hashemy,pathogenic role of the SP/ NK1R system in GBM cells through inhibiting the thioredoxin system. Iran J Basic Med Sci. 2021;24:499–505. https://doi.org/10.22038/ijbms.2021.52902.11945

Article  PubMed  PubMed Central  Google Scholar 

Mozafari M, Ebrahimi S, Darban RA. Hashemy,potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer. Mol Biol Rep. 2022;49:1067–76. https://doi.org/10.1007/s11033-021-06928-3

Article  CAS  PubMed  Google Scholar 

Ebrahimi S, Erfani B, Alalikhan A, Ghorbani H, Farzadnia M, Afshari AR, Mashkani B. and S.I. Hashemy,the in Vitro pro-inflammatory functions of the SP/NK1R system in prostate Cancer: a focus on Nuclear factor-Kappa B (NF-κB) and its pro-inflammatory target genes. Appl Biochem Biotechnol, 1–12 (2023).

Muñoz M. Coveñas,Neurokinin receptor antagonism: a patent review (2014-present). Expert Opin Ther Pat. 2020;30:527–39.

Article  PubMed  Google Scholar 

Muñoz M, Rosso M. The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Investig New Drugs. 2010;28:187–93.

Article  Google Scholar 

Alsaeed MA, Ebrahimi S, Alalikhan A, Hashemi SF. and S.I. Hashemy,The Potential In Vitro Inhibitory Effects of Neurokinin-1 Receptor (NK-1R) Antagonist, Aprepitant, in Osteosarcoma Cell Migration and Metastasis. Biomed Res Int 2022, 8082608 (2022). https://doi.org/10.1155/2022/8082608

Muñoz M. Coveñas,the neurokinin-1 receptor antagonist aprepitant: an intelligent bullet against cancer? Cancers. 2020;12:2682.

Article  PubMed  PubMed Central  Google Scholar 

Nishimura J, Satoh T, Fukunaga M, Takemoto H, Nakata K, Ide Y, Fukuzaki T, Kudo T, Miyake Y, Yasui M, Morita S, Sakai D, Uemura M, Hata T, Takemasa I, Mizushima T, Ohno Y, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M. T.G. Multi-center Clinical Study Group of Osaka,Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. Eur J Cancer. 2015;51:1274–82. https://doi.org/10.1016/j.ejca.2015.03.024

Article  CAS  PubMed  Google Scholar 

Saito H, Yoshizawa H, Yoshimori K, Katakami N, Katsumata N, Kawahara M. Eguchi,Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Ann Oncol. 2013;24:1067–73. https://doi.org/10.1093/annonc/mds541

Article  CAS  PubMed  Google Scholar 

Wu H, Cheng X, Huang F, Shao G, Meng Y, Wang L, Wang T, Jia X, Yang T, Wang X. Fu,Aprepitant sensitizes Acute myeloid leukemia cells to the cytotoxic effects of Cytosine Arabinoside in vitro and in vivo. Drug Des Devel Ther. 2020;14:2413–22. https://doi.org/10.2147/DDDT.S244648

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ebrahimi S, Mirzavi F, Hashemy SI, Khaleghi Ghadiri M, Stummer W. Gorji,the in vitro anti-cancer synergy of neurokinin-1 receptor antagonist, aprepitant, and 5-aminolevulinic acid in glioblastoma. BioFactors. 2023;49:900–11. https://doi.org/10.1002/biof.1953

Article  CAS  PubMed  Google Scholar 

Gu J, Li Z, Zhou J, Sun Z. Bai,Response prediction to oxaliplatin plus 5-fluorouracil chemotherapy in patients with colorectal cancer using a four-protein immunohistochemical model. Oncol Lett. 2019;18:2091–101. https://doi.org/10.3892/ol.2019.10474

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang N, Yin Y, Xu SJ. Chen,5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules. 2008;13:1551–69. https://doi.org/10.3390/molecules13081551

Article  CAS  PubMed  PubMed Central  Google Scholar 

Richards F 2nd, Case LD, White DR, Muss HB, Spurr CL, Jackson DV, Cooper MR, Zekan P, Cruz J, Stuart JJ. Combination chemotherapy (5-fluorouracil, methyl-CCNU, mitomycin C) versus 5-fluorouracil alone for advanced previously untreated colorectal carcinoma. A phase III study of the Piedmont Oncology Association. J Clin Oncol. 1986;4:565–70. https://doi.org/10.1200/JCO.1986.4.4.565

Article  PubMed  Google Scholar 

Aquino A, Prete SP, Greiner JW, Giuliani A, Graziani G, Turriziani M, De Filippi R, Masci G, Bonmassar E. De Vecchis,Effect of the combined treatment with 5-fluorouracil, gamma-interferon or folinic acid on carcinoembryonic antigen expression in colon cancer cells. Clin Cancer Res. 1998;4:2473–81.

CAS  PubMed  Google Scholar 

Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL. Levi,Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18:136–47. https://doi.org/10.1200/JCO.2000.18.1.136

Article  CAS  PubMed  Google Scholar 

Douillard J-Y, Sobrero A, Carnaghi C, Comella P, Diaz-Rubio E, Santoro A. Van Cutsem,metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy. Ann Oncol. 2003;14:ii7–ii12.

Article  PubMed  Google Scholar 

Pagan B, Isidro AA, Coppola D, Chen Z, Ren Y, Wu J. Appleyard,Effect of a neurokinin-1 receptor antagonist in a rat model of colitis-associated colon cancer. Anticancer Res. 2010;30:3345–53.

CAS  PubMed  PubMed Central  Google Scholar 

Ramos-Álvarez I, Moreno P, Mantey SA, Nakamura T, Nuche-Berenguer B, Moody TW, Coy DH. Jensen,insights into bombesin receptors and ligands: highlighting recent advances. Peptides. 2015;72:128–44.

Article  PubMed  PubMed Central  Google Scholar 

Munoz M, Rosso M, Covenas R. The NK-1 receptor antagonist L-732,138 induces apoptosis in human gastrointestinal cancer cell lines. Pharmacol Rep. 2017;69:696–701. https://doi.org/10.1016/j.pharep.2017.02.002

Article  CAS  PubMed  Google Scholar 

Ghahremanloo A, Javid H, Afshari AR. and S.I. Hashemy,Investigation of the Role of Neurokinin-1 Receptor Inhibition Using Aprepitant in the Apoptotic Cell Death through PI3K/Akt/NF-kappaB Signal Transduction Pathways in Colon Cancer Cells. Biomed Res Int 2021, 1383878 (2021). https://doi.org/10.1155/2021/1383878

Garnier A, Vykoukal J, Hubertus J, Alt E, von Schweinitz D, Kappler R, Berger M. Ilmer,targeting the neurokinin-1 receptor inhibits growth of human colon cancer cells. Int J Oncol. 2015;47:151–60. https://doi.org/10.3892/ijo.2015.3016

Article  CAS  PubMed  Google Scholar 

Kast RE, Ramiro S, Llado S, Toro S, Covenas R. Munoz,Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells. J Neurooncol. 2016;126:425–31. https://doi.org/10.1007/s11060-015-1996-6

Article  CAS  PubMed  Google Scholar 

R.E. Kast,Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug. J Clin Pharm Ther 35, 657–63 (2010). https://doi.org/10.1111/j.1365-2710.2009.01148.x

Ebrahimi S, Mirzavi F, Aghaee-Bakhtiari SH, Hashemy SI. SP/NK1R system regulates carcinogenesis in prostate cancer: shedding light on the antitumoral function of aprepitant. Biochim et Biophys Acta (BBA)-Molecular Cell Res. 2022;1869:119221.

Article  CAS  Google Scholar